| Drug Name: | Gabapentin (60142-96-3) |
|---|---|
| PubChem ID: | 3446 |
| SMILES: | C1CCC(CC1)(CC(=O)O)CN |
| InchiKey: | UGJMXCAKCUNAIE-UHFFFAOYSA-N |
| Therapeutic Category: | Analgesics, Anti-Anxiety Agents, Anti-Dyskinesia Agents, Anticonvulsants, Antimanic Agents, Antiparkinson Agents, Calcium Channel Blockers, Cardiovascular Agents, Central Nervous System Agents, Central Nervous System Depressants, Excitatory Amino Acid Agents, Excitatory Amino Acid Antagonists, Membrane Transport Modulators, Neurotransmitter Agents, Peripheral Nervous System Agents, Psychotropic Drugs, Sensory System Agents, Tranquilizing Agents |
| Molecular Weight (dalton) | : | 171.24 |
| LogP | : | 1.3703 |
| Ring Count | : | 0 |
| Hydrogen Bond Acceptor Count | : | 2 |
| Hydrogen Bond Donor Count | : | 2 |
| Total Polar Surface Area | : | 63.32 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Akathisia | D(1A) dopamine receptor (P21728) | Dopamine receptor hypersensitivity hypothesis and the hypothesis of mitochondrial respiratory chain inhibition are evidences for the hypotheses of the pathogenetic mechanisms leading to akathisia(extrapyramidal side effects). [ ADR Type 1 ] | Cell-mediated side effects of psychopharmacological treatment |
| Allodynia | Gamma-aminobutyric acid (GABA-A) receptor (Q5SUY9) | Spinal gamma-aminobutyric acid (GABA) receptors have been shown to modulate post-nerve injury-induced allodynia [ ADR Type 1 ] | Effect of subarachnoid gabapentin on tactile-evoked allodynia in a surgically induced neuropathic pain model in the rat |
| Anxiety | 5-hydroxytryptamine 3 receptor (P46098) | Adverse effects may@ however@ occur through the stimulation of different serotonin receptor subtypes (5-HT2A@ 5-HT2B@ and 5-HT3)@ leading to anxiety [ ADR Type 2 ] | Cell-mediated side effects of psychopharmacological treatment |
| Anxiety | 5-hydroxytryptamine receptor 2A (P28223) | Adverse effects may@ however@ occur through the stimulation of different serotonin receptor subtypes (5-HT2A@ 5-HT2B@ and 5-HT3)@ leading to anxiety [ ADR Type 2 ] | Cell-mediated side effects of psychopharmacological treatment |
| Anxiety | 5-hydroxytryptamine receptor 2B (P41595) | Adverse effects may@ however@ occur through the stimulation of different serotonin receptor subtypes (5-HT2A@ 5-HT2B@ and 5-HT3)@ leading to anxiety [ ADR Type 2 ] | Cell-mediated side effects of psychopharmacological treatment |
| Anxiety | Alpha-1A adrenergic receptor (P35348) | Significant adverse effects may occur through the interaction of the antidepressants with other receptors believed not to be related to the therapeutic action@ most importantly the muscarinic acetylcholine receptor (M)@ the histamine-1 (H1) receptor and the alpha-1 (alpha 1) adrenergic receptor@leading to anxiety. [ ADR Type 2 ] | Cell-mediated side effects of psychopharmacological treatment |
| Anxiety | Histamine H1 receptor (P35367) | Significant adverse effects may occur through the interaction of the antidepressants with other receptors believed not to be related to the therapeutic action@ most importantly the muscarinic acetylcholine receptor (M)@ the histamine-1 (H1) receptor and the alpha-1 (alpha 1) adrenergic receptor@leading to anxiety [ ADR Type 2 ] | Cell-mediated side effects of psychopharmacological treatment |
| Anxiety | Muscarinic acetylcholine receptor M1 (P11229) | Significant adverse effects may occur through the interaction of the antidepressants with other receptors believed not to be related to the therapeutic action@ most importantly the muscarinic acetylcholine receptor (M)@ the histamine-1 (H1) receptor and the alpha-1 (alpha 1) adrenergic receptor@leading to anxiety [ ADR Type 2 ] | Cell-mediated side effects of psychopharmacological treatment |
| Diabetic Kidney Disease | Glucosamine--fructose-6-phosphate aminotransferase (Q06210) | Increased flux through the hexosamine biosynthetic pathway with glutamine:fructose-6-phosphate-amidotransferase (GFAT) as rate-limiting enzyme has been linked to the enhanced bioactivity of the prosclerotic cytokine transforming growth factor beta1 (TGF-beta1) in fibrotic complications@ particularly in diabetic kidney disease. [ ADR Type 2 ] | Overexpression of glutamine:fructose-6-phosphate-amidotransferase induces transforming growth factor-beta1 synthesis in NIH-3T3 fibroblasts |
| Diabetic Kidney Disease | Transforming growth factor beta (P01137) | Increased flux through the hexosamine biosynthetic pathway with glutamine:fructose-6-phosphate-amidotransferase (GFAT) as rate-limiting enzyme has been linked to the enhanced bioactivity of the prosclerotic cytokine transforming growth factor beta1 (TGF-beta1) in fibrotic complications, particularly in diabetic kidney disease. [ ADR Type 2 ] | Overexpression of glutamine:fructose-6-phosphate-amidotransferase induces transforming growth factor-beta1 synthesis in NIH-3T3 fibroblasts |
| Dystonic Reactions | D(1A) dopamine receptor (P21728) | Dopamine receptor hypersensitivity hypothesis and the hypothesis of mitochondrial respiratory chain inhibition are evidences for the hypotheses of the pathogenetic mechanisms leading to dystonic reactions(extrapyramidal side effects) [ ADR Type 1 ] | Cell-mediated side effects of psychopharmacological treatment |
| Nausea | 5-hydroxytryptamine 3 receptor (P46098) | Adverse effects may@ however@ occur through the stimulation of different serotonin receptor subtypes (5-HT2A@ 5-HT2B@ and 5-HT3)@ leading to nausea [ ADR Type 2 ] | Cell-mediated side effects of psychopharmacological treatment |
| Nausea | 5-hydroxytryptamine receptor 2A (P28223) | Adverse effects may@ however@ occur through the stimulation of different serotonin receptor subtypes (5-HT2A@ 5-HT2B@ and 5-HT3)@ leading to nausea. [ ADR Type 2 ] | Cell-mediated side effects of psychopharmacological treatment |
| Nausea | 5-hydroxytryptamine receptor 2B (P41595) | Adverse effects may@ however@ occur through the stimulation of different serotonin receptor subtypes (5-HT2A@ 5-HT2B@ and 5-HT3)@ leading to nausea [ ADR Type 2 ] | Cell-mediated side effects of psychopharmacological treatment |
| Nausea | Alpha-1A adrenergic receptor (P35348) | Significant adverse effects may occur through the interaction of the antidepressants with other receptors believed not to be related to the therapeutic action@ most importantly the muscarinic acetylcholine receptor (M)@ the histamine-1 (H1) receptor and the alpha-1 (alpha 1) adrenergic receptor@leading to nausea. [ ADR Type 2 ] | Cell-mediated side effects of psychopharmacological treatment |
| Nausea | Histamine H1 receptor (P35367) | Significant adverse effects may occur through the interaction of the antidepressants with other receptors believed not to be related to the therapeutic action@ most importantly the muscarinic acetylcholine receptor (M)@ the histamine-1 (H1) receptor and the alpha-1 (alpha 1) adrenergic receptor@leading to nausea [ ADR Type 2 ] | Cell-mediated side effects of psychopharmacological treatment |
| Nausea | Muscarinic acetylcholine receptor M1 (P11229) | Significant adverse effects may occur through the interaction of the antidepressants with other receptors believed not to be related to the therapeutic action@ most importantly the muscarinic acetylcholine receptor (M)@ the histamine-1 (H1) receptor and the alpha-1 (alpha 1) adrenergic receptor@leading to nausea. [ ADR Type 2 ] | Cell-mediated side effects of psychopharmacological treatment |
| Parkinsonism | D(1A) dopamine receptor (P21728) | Dopamine receptor hypersensitivity hypothesis and the hypothesis of mitochondrial respiratory chain inhibition are evidences for the hypotheses of the pathogenetic mechanisms leading to parkinsonism(extrapyramidal side effects) [ ADR Type 1 ] | Cell-mediated side effects of psychopharmacological treatment |
| Sleep Disturbances | 5-hydroxytryptamine 3 receptor (P46098) | Adverse effects may@ however@ occur through the stimulation of different serotonin receptor subtypes (5-HT2A@ 5-HT2B@ and 5-HT3)@ leading to sleep disturbances [ ADR Type 2 ] | Cell-mediated side effects of psychopharmacological treatment |
| Sleep Disturbances | 5-hydroxytryptamine receptor 2A (P28223) | Adverse effects may@ however@ occur through the stimulation of different serotonin receptor subtypes (5-HT2A@ 5-HT2B@ and 5-HT3)@ leading to sleep disturbances [ ADR Type 2 ] | Cell-mediated side effects of psychopharmacological treatment |
| Sleep Disturbances | 5-hydroxytryptamine receptor 2B (P41595) | Adverse effects may@ however@ occur through the stimulation of different serotonin receptor subtypes (5-HT2A@ 5-HT2B@ and 5-HT3)@ leading to sleep disturbances [ ADR Type 2 ] | Cell-mediated side effects of psychopharmacological treatment |
| Sleep Disturbances | Alpha-1A adrenergic receptor (P35348) | Significant adverse effects may occur through the interaction of the antidepressants with other receptors believed not to be related to the therapeutic action@ most importantly the muscarinic acetylcholine receptor (M)@ the histamine-1 (H1) receptor and the alpha-1 (alpha 1) adrenergic receptor@leading to sleep disturbances. [ ADR Type 2 ] | Cell-mediated side effects of psychopharmacological treatment |
| Sleep Disturbances | Histamine H1 receptor (P35367) | Significant adverse effects may occur through the interaction of the antidepressants with other receptors believed not to be related to the therapeutic action@ most importantly the muscarinic acetylcholine receptor (M)@ the histamine-1 (H1) receptor and the alpha-1 (alpha 1) adrenergic receptor@leading to sleep disturbances. [ ADR Type 2 ] | Cell-mediated side effects of psychopharmacological treatment |
| Sleep Disturbances | Muscarinic acetylcholine receptor M1 (P11229) | Significant adverse effects may occur through the interaction of the antidepressants with other receptors believed not to be related to the therapeutic action@ most importantly the muscarinic acetylcholine receptor (M)@ the histamine-1 (H1) receptor and the alpha-1 (alpha 1) adrenergic receptor@leading to sleep disturbances. [ ADR Type 2 ] | Cell-mediated side effects of psychopharmacological treatment |
| Tardive Dyskinesias | D(1A) dopamine receptor (P21728) | Dopamine receptor hypersensitivity hypothesis and the hypothesis of mitochondrial respiratory chain inhibition are evidences for the hypotheses of the pathogenetic mechanisms leading to tardive dyskinesias(extrapyramidal side effects). [ ADR Type 1 ] | Cell-mediated side effects of psychopharmacological treatment |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category